In female Sprague Dawley rats fed with HFD, EGCG treatment (50 mg/kg, i.p. injection, 3 times per week, 8 weeks) was able to attenuate oxidative stress, steatosis, steatohepatitis, necrosis, and fibrosis in the liver through the NF-κB (limiting iNOS, COX-2, and TNF-α), TGF/SMAD (regulating matrix metalloproteinase-2/MMP-2, TIMP-2, and α-SMA), and PI3K/Akt/FoxO1 (relating to proliferation and trans-differentiation of HSCs) pathways [140]. This evidence concerns the gene MMP2 and steatosis.